吉林医学
吉林醫學
길림의학
JILIN MEDICAL JOURANL
2014年
25期
5544-5546
,共3页
王根和%方平%陈雍%左刚%吴怡青%朱元贞
王根和%方平%陳雍%左剛%吳怡青%硃元貞
왕근화%방평%진옹%좌강%오이청%주원정
腹腔热灌注化疗联合静脉化疗%单纯静脉化疗%腹腔转移癌%腹痛
腹腔熱灌註化療聯閤靜脈化療%單純靜脈化療%腹腔轉移癌%腹痛
복강열관주화료연합정맥화료%단순정맥화료%복강전이암%복통
Intraperitoneal hyperthermic perfusion chemotherapy%Intravenous chemotherapy%Peritoneal metastases%Abdominal pain
目的:对比腹腔热灌注化疗联合静脉化疗与单纯静脉化疗治疗腹腔转移癌的不良反应以及疗效。方法:采用自身对照方法,选取56例序贯进行腹腔热灌注化疗联合静脉化疗和单纯静脉化疗患者,分别观察腹腔热灌注化疗联合静脉化疗和单纯静脉化疗的毒副反应并对比,同时随访生存情况。结果:腹腔热灌注化疗联合静脉化疗与单纯静脉化疗相比,腹痛发生率较高(25%与8.9%),Ⅲ﹢Ⅳ白细胞减少较低(16.%与21%),而胃肠道反应比较,差异无统计学意义( P﹥0.05),中位总生存期为22个月。结论:对比单纯静脉化疗,腹腔热灌注化疗联合静脉化疗治疗腹腔转移癌安全有效,但腹痛发生率较高。
目的:對比腹腔熱灌註化療聯閤靜脈化療與單純靜脈化療治療腹腔轉移癌的不良反應以及療效。方法:採用自身對照方法,選取56例序貫進行腹腔熱灌註化療聯閤靜脈化療和單純靜脈化療患者,分彆觀察腹腔熱灌註化療聯閤靜脈化療和單純靜脈化療的毒副反應併對比,同時隨訪生存情況。結果:腹腔熱灌註化療聯閤靜脈化療與單純靜脈化療相比,腹痛髮生率較高(25%與8.9%),Ⅲ﹢Ⅳ白細胞減少較低(16.%與21%),而胃腸道反應比較,差異無統計學意義( P﹥0.05),中位總生存期為22箇月。結論:對比單純靜脈化療,腹腔熱灌註化療聯閤靜脈化療治療腹腔轉移癌安全有效,但腹痛髮生率較高。
목적:대비복강열관주화료연합정맥화료여단순정맥화료치료복강전이암적불량반응이급료효。방법:채용자신대조방법,선취56례서관진행복강열관주화료연합정맥화료화단순정맥화료환자,분별관찰복강열관주화료연합정맥화료화단순정맥화료적독부반응병대비,동시수방생존정황。결과:복강열관주화료연합정맥화료여단순정맥화료상비,복통발생솔교고(25%여8.9%),Ⅲ﹢Ⅳ백세포감소교저(16.%여21%),이위장도반응비교,차이무통계학의의( P﹥0.05),중위총생존기위22개월。결론:대비단순정맥화료,복강열관주화료연합정맥화료치료복강전이암안전유효,단복통발생솔교고。
Objective To compare efficacy and side effect of intraperitoneal hyperthermic perfusion chemotherapy combined with intra-venous chemotherapy versus intravenous chemotherapy in patients with peritoneal carcinomatosis. Method Fifty six patients were selected on self-control design principle. intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy or intrave-nous chemotherapy were conducted sequential. Efficacy and Side Effect were observed and survival were followed. Results Contrast to intra-venous chemotherapy,intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy was safe. the ratio of abdominal pain was higher and the ratio of grade Ⅲ - Ⅳ leucopenia was lower. the meidian survival time was 22 months. Conclusion Contrast to intravenous chemotherapy,intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy is safe and effective in patients with peritoneal carcinomatosis. but the ratio of abdominal pain is higher.